

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please cancel claims 1-8 and 10, and add new claims 14-18, as follows:

1-8. (Cancelled).

9. (Original). A method for prophylaxis of migraine which comprises administering a therapeutically effective amount of a selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors to a patient.

10. (Cancelled).

11. (Previously presented). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises:

a) a 5-HT_{2B} receptor antagonistic compound as a first ingredient having a selective binding affinity to the 5-HT_{2B} receptor, and

b) a 5-HT₇ receptor antagonistic compound as a second ingredient having a selective binding affinity to the 5-HT₇ receptor.

12. (Previously presented). The method of claim 9, wherein the selective dual antagonist for the 5-HT_{2B} and 5-HT₇ receptors comprises a dual antagonistic compound for the 5-HT_{2B} and 5-HT₇ receptors having a selective binding affinity to both of the 5-HT_{2B} and 5-HT₇ receptors.

13. (Currently Amended). The method of claim 9, wherein the ~~binding affinity~~ Ki or IC₅₀ values for the 5-HT_{2B} and 5-HT₇ receptors ~~[[is]]are~~ respectively one-hundredth or ~~more to the~~ less of those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

14. (New). The method of claim 9, wherein the binding affinities for the 5-HT_{2B} and 5-HT₇ receptors are higher than those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

15. (New). The method of claim 9, wherein the binding affinities for the 5-HT_{2B} and 5-HT₇ receptors are higher than those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

16. (New). The method of claim 9, wherein the Ki or IC₅₀ values for the 5-HT_{2B} and 5-HT₇ receptors are respectively one-tenth or less of those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

17. (New). The method of claim 9, wherein the Ki or IC₅₀ values for the 5-HT_{2B} and 5-HT₇ receptors are respectively one-tenth or less of those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.

18. (New). The method of claim 9, wherein the K_i or IC_{50} values for the 5-HT_{2B} and 5-HT₇ receptors are respectively one-hundredth or less of those of each of α_1 , M₁, D₂, 5-HT_{1A}, 5-HT_{1B}, 5-HT₃, 5-HT₄ and 5-HT₆ receptors.